Scleroderma, Diffuse: Clinical Trials

7 trials for Scleroderma, Diffuse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 enrolling by invitation, 1 withdrawn. 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 47Completed 3, Terminated 2, Enrolling by invitation 1, Withdrawn 1

Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies
Phase 4Enrolling by invitationRegion Skane2402024-12-172025-01-10
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
Upfront autologous HSCT - Systemic Sclerosis, Systemic Scleroses, Diffuse
Phase 4CompletedUMC Utrecht602020-09-172026-03-24
Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases
Polydeoxyribonucleotides - Scleroderma Disease
Phase 4TerminatedMastelli S.r.l252016-11-082021-09-16
Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis
Lactobacillus - Scleroderma
Phase 4WithdrawnUniversity of Michigan2012-02-012016-12-22
Pulmonary Artery Remodelling With Bosentan
bosentan - Hypertension, Pulmonary
Phase 4CompletedActelion112006-05-312026-06-03
Comparison of Esophageal and Anorectal Manometry Catheters
Air filled balloon catheter, Solid state catheter - Achalasia, Nutcracker Esophagus
Phase 4TerminatedUniversity of Utah52004-01-012008-01-16
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Pletal - Raynaud's Disease
Phase 4CompletedOtsuka America Pharmaceutical752001-10-012005-07-19

Narrower conditions

Arthritis (1)  ·  Arthritis, Juvenile (1)  ·  Arthritis, Psoriatic (1)  ·  Esophageal Achalasia (1)  ·  Esophageal Motility Disorders (1)  ·  Esophageal Spasm, Diffuse (1)  ·  Fecal Incontinence (1)  ·  Gastroesophageal Reflux (1)  ·  Giant Cell Arteritis (1)  ·  Herpes Zoster (1)  ·  Hypertension (1)  ·  Hypertension, Pulmonary (1)  ·  Mixed Connective Tissue Disease (1)  ·  Polymyalgia Rheumatica (1)

Broader conditions

Connective Tissue Diseases (7)  ·  Skin Diseases (7)  ·  Skin and Connective Tissue Diseases (7)  ·  Scleroderma, Systemic (6)  ·  Cardiovascular Diseases (3)  ·  Vascular Diseases (3)  ·  Deglutition Disorders (2)  ·  Digestive System Diseases (2)  ·  Esophageal Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Skin Diseases, Vascular (2)  ·  Arteritis (1)  ·  Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Bone Diseases (1)

Interventions

Bosentan (1)  ·  Cilostazol (1)  ·  Lacteol (1)  ·  Polydeoxyribonucleotides (1)  ·  Vaccination (1)

Sponsors

Actelion (1)  ·  Mastelli S.r.l (1)  ·  Otsuka America Pharmaceutical (1)  ·  Region Skane (1)  ·  UMC Utrecht (1)  ·  University of Michigan (1)  ·  University of Utah (1)

Countries

Italy (2)  ·  United States (2)  ·  Australia (1)  ·  Netherlands (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

David Celermajer, Professor (1)  ·  Jacob M van Laar, MD PhD (1)  ·  John C Fang, M.D. (1)  ·  Julia Spierings (1)  ·  Simona Muratori, Dr (1)

Results publications

PMID 33737437

NIH funding

2023 (1)